Cargando…

The potential therapeutic role of PTR1 gene in non‐healing anthroponotic cutaneous leishmaniasis due to Leishmania tropica

BACKGROUND: Drug resistance is a common phenomenon frequently observed in countries where leishmaniasis is endemic. Due to the production of the pteridine reductase enzyme (PTR1), drugs lose their efficacy, and consequently, the patient becomes unresponsive to treatment. This study aimed to compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Sezavar, Monireh, Sharifi, Iraj, Ghasemi Nejad Almani, Pooya, Kazemi, Bahram, Davoudi, Noushin, Salari, Samira, Salarkia, Ehsan, Khosravi, Ahmad, Bamorovat, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957997/
https://www.ncbi.nlm.nih.gov/pubmed/33283321
http://dx.doi.org/10.1002/jcla.23670
_version_ 1783664765777739776
author Sezavar, Monireh
Sharifi, Iraj
Ghasemi Nejad Almani, Pooya
Kazemi, Bahram
Davoudi, Noushin
Salari, Samira
Salarkia, Ehsan
Khosravi, Ahmad
Bamorovat, Mehdi
author_facet Sezavar, Monireh
Sharifi, Iraj
Ghasemi Nejad Almani, Pooya
Kazemi, Bahram
Davoudi, Noushin
Salari, Samira
Salarkia, Ehsan
Khosravi, Ahmad
Bamorovat, Mehdi
author_sort Sezavar, Monireh
collection PubMed
description BACKGROUND: Drug resistance is a common phenomenon frequently observed in countries where leishmaniasis is endemic. Due to the production of the pteridine reductase enzyme (PTR1), drugs lose their efficacy, and consequently, the patient becomes unresponsive to treatment. This study aimed to compare the in vitro effect of meglumine antimoniate (MA) on non‐ healing Leishmania tropica isolates and on MA transfected non‐healing one to PTR1. METHODS: Two non‐healing and one healing isolates of L. tropica were collected from patients who received two courses or one cycle of intralesional MA along with biweekly liquid nitrogen cryotherapy or systemic treatment alone, respectively. After confirmation of L. tropica isolates by polymerase chain reaction (PCR), the recombinant plasmid pcDNA‐rPTR (antisense) was transfected via electroporation and cultured on M199. Isolates in form of promastigotes were treated with different concentrations of MA and read using an enzyme‐linked immunosorbent assay (ELISA) reader and the half inhibitory concentration (IC(50)) value was calculated. The amastigotes were grown in mouse macrophages and were similarly treated with various concentrations of MA. The culture glass slides were stained, and the mean number of intramacrophage amastigotes and infected macrophages were assessed in triplicate for both stages. RESULTS: All three transfected isolates displayed a reduction in optical density compared with the promastigotes in respective isolates, although there was no significant difference between non‐healing and healing isolates. In contrast, in the clinical form (amastigotes), there was a significant difference between non‐healing and healing isolates (p < 0.05). CONCLUSION: The results indicated that the PTR1 gene reduced the efficacy of the drug, and its inhibition by antisense and could improve the treatment of non‐healing cases. These findings have future implications in the prophylactic and therapeutic modality of non‐ healing Leishmania isolates to drug.
format Online
Article
Text
id pubmed-7957997
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-79579972021-03-19 The potential therapeutic role of PTR1 gene in non‐healing anthroponotic cutaneous leishmaniasis due to Leishmania tropica Sezavar, Monireh Sharifi, Iraj Ghasemi Nejad Almani, Pooya Kazemi, Bahram Davoudi, Noushin Salari, Samira Salarkia, Ehsan Khosravi, Ahmad Bamorovat, Mehdi J Clin Lab Anal Research Articles BACKGROUND: Drug resistance is a common phenomenon frequently observed in countries where leishmaniasis is endemic. Due to the production of the pteridine reductase enzyme (PTR1), drugs lose their efficacy, and consequently, the patient becomes unresponsive to treatment. This study aimed to compare the in vitro effect of meglumine antimoniate (MA) on non‐ healing Leishmania tropica isolates and on MA transfected non‐healing one to PTR1. METHODS: Two non‐healing and one healing isolates of L. tropica were collected from patients who received two courses or one cycle of intralesional MA along with biweekly liquid nitrogen cryotherapy or systemic treatment alone, respectively. After confirmation of L. tropica isolates by polymerase chain reaction (PCR), the recombinant plasmid pcDNA‐rPTR (antisense) was transfected via electroporation and cultured on M199. Isolates in form of promastigotes were treated with different concentrations of MA and read using an enzyme‐linked immunosorbent assay (ELISA) reader and the half inhibitory concentration (IC(50)) value was calculated. The amastigotes were grown in mouse macrophages and were similarly treated with various concentrations of MA. The culture glass slides were stained, and the mean number of intramacrophage amastigotes and infected macrophages were assessed in triplicate for both stages. RESULTS: All three transfected isolates displayed a reduction in optical density compared with the promastigotes in respective isolates, although there was no significant difference between non‐healing and healing isolates. In contrast, in the clinical form (amastigotes), there was a significant difference between non‐healing and healing isolates (p < 0.05). CONCLUSION: The results indicated that the PTR1 gene reduced the efficacy of the drug, and its inhibition by antisense and could improve the treatment of non‐healing cases. These findings have future implications in the prophylactic and therapeutic modality of non‐ healing Leishmania isolates to drug. John Wiley and Sons Inc. 2020-12-07 /pmc/articles/PMC7957997/ /pubmed/33283321 http://dx.doi.org/10.1002/jcla.23670 Text en © 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Sezavar, Monireh
Sharifi, Iraj
Ghasemi Nejad Almani, Pooya
Kazemi, Bahram
Davoudi, Noushin
Salari, Samira
Salarkia, Ehsan
Khosravi, Ahmad
Bamorovat, Mehdi
The potential therapeutic role of PTR1 gene in non‐healing anthroponotic cutaneous leishmaniasis due to Leishmania tropica
title The potential therapeutic role of PTR1 gene in non‐healing anthroponotic cutaneous leishmaniasis due to Leishmania tropica
title_full The potential therapeutic role of PTR1 gene in non‐healing anthroponotic cutaneous leishmaniasis due to Leishmania tropica
title_fullStr The potential therapeutic role of PTR1 gene in non‐healing anthroponotic cutaneous leishmaniasis due to Leishmania tropica
title_full_unstemmed The potential therapeutic role of PTR1 gene in non‐healing anthroponotic cutaneous leishmaniasis due to Leishmania tropica
title_short The potential therapeutic role of PTR1 gene in non‐healing anthroponotic cutaneous leishmaniasis due to Leishmania tropica
title_sort potential therapeutic role of ptr1 gene in non‐healing anthroponotic cutaneous leishmaniasis due to leishmania tropica
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957997/
https://www.ncbi.nlm.nih.gov/pubmed/33283321
http://dx.doi.org/10.1002/jcla.23670
work_keys_str_mv AT sezavarmonireh thepotentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT sharifiiraj thepotentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT ghaseminejadalmanipooya thepotentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT kazemibahram thepotentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT davoudinoushin thepotentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT salarisamira thepotentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT salarkiaehsan thepotentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT khosraviahmad thepotentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT bamorovatmehdi thepotentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT sezavarmonireh potentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT sharifiiraj potentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT ghaseminejadalmanipooya potentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT kazemibahram potentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT davoudinoushin potentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT salarisamira potentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT salarkiaehsan potentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT khosraviahmad potentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica
AT bamorovatmehdi potentialtherapeuticroleofptr1geneinnonhealinganthroponoticcutaneousleishmaniasisduetoleishmaniatropica